Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor

Pharmaceutical Research

Volumn 21, Issue 3, 2004, Pages 458-466

  Hollins, Andrew J ^a   Benboubetra, Mustapha ^a,b   Omidi, Yadollah ^a,c   Zinselmeyer, Bernd H ^d,e   Schatzlein, Andreas G ^e   Uchegbu, Ijeoma F ^d   Akhtar, Saghir ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b FERHAT ABBAS UNIVERSITY   (Algeria)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

A431 cells; Antisense oligodeoxynucleotide; Epidermal growth factor receptor; Gene delivery; Poly(propylenimine) dendrimer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DENDRIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; IMINE; POLY(PROPYLENIMINE); UNCLASSIFIED DRUG; OLIGONUCLEOTIDE;

ARTICLE; CANCER GROWTH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; FLOW CYTOMETRY;

DENDRIMERS; FLOW CYTOMETRY; HUMANS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 1542511346     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000019300.04836.51     Document Type: Article

References (39)

1. A. M. Gewirtz, D. L. Sokol, and M. Z. Ratajczak. Nucleic acid therapeutics: state of the art and future prospects. Blood 92:712-736 (1998).
2. M. Thomas and A. M. Klibanov. Non-viral gene therapy: polycation-mediated DNA delivery. Appl. Microbiol. Biotechnol. 62:27-34 (2003).
3. M. Nishikawa and L. Huang. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum. Gene Ther. 12:861-870 (2001).
4. G. Y. Wu, J. M. Wilson, F. Shalaby, M. Grossman, D. A. Shafritz, and C. H. Wu. Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. J. Biol. Chem. 266:14338-14342 (1991).
5. O. Boussif, F. Lezoualc'h, M. A. Zanta, M. D. Mergny, D. Scherman, B. Demeneix, and J. P. Behr. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 92:7297-7301 (1995).
6. J. F. Kukowska-Latallo, A. U. Bielinska, J. Johnson, R. Spindler, D. A. Tomalia, and J. R. Baker Jr. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. U. S. A. 93:4897-4902 (1996).
7. Y. Lim, S. M. Kim, Y. Lee, W. Lee, T. Yang, M. Lee, and H. Suh, and J. Park. Cationic hyperbranched poly(amino ester). a novel class of DNA condensing molecule with cationic surface, biodegradable three-dimensional structure, and tertiary amine groups in the interior. J. Am. Chem. Soc. 123:2460-2461 (2001).
8. R. C. van Duijvenbode, M. Borkovec, and G. J. M. Koper. Acid-base properties of poly(propylene imine) dendrimers. Polymer 39:2657-2664 (1998).
9. A. Bielinska, J. F. Kukowska-Latallo, J. Johnson, D. A. Tomalia, and J. R. Baker Jr. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 24:2176-2182 (1996).
10. M. X. Tang, C. T. Redemann, and F. C. Szoka Jr. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug. Chem. 7:703-714 (1996).
11. A. U. Bielinska, C. Chen, J. Johnson, and J. R. Baker Jr. DNA complexing with polyamidoamine dendrimers: implications for transfection. Bioconjug. Chem. 10:843-850 (1999).
12. I. Toth, T. Sakthivel, A. F. Wilderspin, H. Bayele, M. O'Donnell, D. J. Perry, K. J. Pasi, C. A. Lee, and A. T. Florence. Novel cationic lipidic peptide dendrimer vectors - in vitro gene delivery. STP Pharma Sci. 9:93-99 (1999).
13. N. Malik, R. Wiwattanapatapee, R. Klopsch, K. Lorenz, H. Frey, J. W. Weener, E. W. Meijer, W. Paulus, and R. Duncan. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 1251-labelled polyamidoamine dendrimers in vivo. J. Control. Rel. 65:133-148 (2000).
14. G. Pistolis, A. Malliaris, D. Tsiourvas, and C. M. Paleos. Poly(propyleneimine) dendrimers as pH-sensitive controlled-release systems. Chem. Eur. J. 5:1440-1444 (1999).
15. C. L. Gebhart and A. V. Kabanov. Evaluation of polyplexes as gene transfer agents. J. Control. Rel. 73:401-416 (2001).
16. B. H. Zinselmeyer, S. P. Mackay, A. G. Schatzlein, and I. F. Uchegbu. The lower-generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm. Res. 19:960-967 (2002).
17. C. L. Arteaga. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7:31-39 (2002).
18. J. Baselga. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7:2-8 (2002).
19. A. K. Petch, M. Sohail, M. D. Hughes, I. Benter, J. Darling, E. M. Southern, and S. Akhtar. Messenger RNA expression profiling of genes involved in epidermal growth factor signalling in human cancer cells treated with scanning array-designed antisense oligonucleotides. Biochem. Pharmacol. 66:819-830 (2003).
20. Y. Shoji, S. Akhtar, A. Periasamy, B. Herman, and R. L. Juliano. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res. 19: 5543-5550 (1991).
21. R. L. Juliano and S. Akhtar. Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Res. Dev. 2:165-176 (1992).
22. P. L. Fell, A. J. Hudson, M. A. Reynolds, N. Usman, and S. Akhtar. Cellular uptake properties of a 2′-amino/2′-O-methyl-modified chimeric hammerhead ribozyme targeted to the epider-mal growth factor receptor mRNA. Antisense Nucleic Acid Drug Dev. 7:319-326 (1997).
23. J. P. Richard, K. Melikov, E. Vives, C. Ramos, B. Verbeure, M. J. Gait, L. V. Chernomordik, and B. Lebleu. Cell-penetrating peptides: a reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278:585-590 (2003).
24. P. E. Thoren, D. Persson, P. Isakson, M. Goksor, A. Onfelt, and B. Norden. Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells. Biochem. Biophys. Res. Commun. 307:100-107 (2003).
25. G. Drin, S. Cottin, E. Blanc, A. R. Rees, and J. Temsamani. Studies on the internalization mechanism of cationic cell-penetrating peptides. J. Biol. Chem. 278:31192-31201 (2003).
26. A. Ziegler, X. L. Blatter, A. Seelig, and J. Seelig. Protein transduction domains of HIV-1 and SIV TAT interact with charged lipid vesicles. Binding mechanism and thermodynamic analysis. Biochemistry 42:9185-9194 (2003).
27. J. M. Coulson, D. R. Poyner, A. Chantry, W. J. Irwin, and S. Akhtar. A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells. Mol Pharmacol 50:314-325 (1996).
28. I. Jaaskelainen and A. Urtti. Cell membranes as barriers for the use of antisense therapeutic agents. Mini Rev. Med. Chem. 2:307-318 (2002).
29. S. Akhtar, M. D. Hughes, A. Khan, M. Bibby, M. Hussain, Q. Nawaz, J. Double, and P. Sayyed. The delivery of antisense therapeutics. Adv. Drug Deliv. Rev. 44:3-21 (2000).
30. M. D. Hughes, M. Hussain, Q. Nawaz, P. Sayyed, and S. Akhtar. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov. Today 6:303-315 (2001).
31. M. Hussain, M. Shchepinov, M. Sohail, A. J. Hollins, E. M. Southern, and S. Akhtar. A novel anionic dendrimer for improved delivery of antisense oligonucleotides. Submitted (2004).
32. S. Dheur, N. Dias, A. van Aerschot, P. Herdewijn, T. Bettinger, J. S. Remy, C. Helene, and E. T. Saison-Behmoaras. Polyethylenimine but not cationic lipid improves antisense activity of 3′-capped phosphodiester oligonucleotides. Antisense Nucleic Acid Drug Dev. 9:515-525 (1999).
33. R. Delong, K. Stephenson, T. Loftus, M. Fisher, S. Alahari, A. Nolting, and R. L. Juliano. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J. Pharm. Sci. 86:762-764 (1997).
34. N. Sato, H. Kobayashi, T. Saga, Y. Nakamoto, T. Ishimori, K. Togashi, Y. Fujibayashi, J. Konishi, and M. W. Brechbiel. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin. Cancer Res. 7:3606-3612 (2001).
35. W. T. Godbey, K. K. Wu, and A. G. Mikos. Poly(ethylenimine) and its role in gene delivery. J. Control. Rel. 60:149-160 (1999).
36. P. de Diesbach. F. N'Kuli, C. Berens, E. Sonveaux, M. Monsigny, A. C. Roche, and P. J. Courtoy. Receptor-mediated endocytosis of phosphodiester oligonucleotides in the HepG2 cell line: evidence for non-conventional intracellular trafficking. Nucleic Acids Res. 30:1512-1521 (2002).
37. M. Berton, L. Benimetskaya, E. Allemann, C. A. Stein, and R. Gurny. Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization. Eur. J. Pharm. Biopharm. 47:119-123 (1999).
38. A. R. Thierry, E. Vives, J. P. Richard, P. Prevot, C. Martinand-Mari, I. Robbins, and B. Lebleu. Cellular uptake and intracellular fate of antisense oligonucleotides. Curr. Opin. Mol. Ther. 5:133-138 (2003).
39. T. Bieber, W. Meissner, S. Kostin, A. Niemann, and H. P. Elsasser. Intracellular route and transcriptional competence of polyethylenimine-DNA complexes. J. Control Rel. 82:441-454 (2002).